Comparative Analysis of Resmetirom vs. FGF21 Analogs vs. GLP-1 Agonists in MASLD and MASH: Network Meta-Analysis of Clinical Trials

Introduction: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic-Dysfunction Associated Steatohepatitis (MASH) are linked to obesity, type 2 diabetes, and metabolic syndrome, increasing liver-related morbidity and cardiovascular risk. Recent therapies, including Resmetiro...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Hazem Ayesh, Azizullah Beran, Sajida Suhail, Suhail Ayesh, Kevin Niswender
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2024-10-01
coleção:	Biomedicines
Assuntos:	Resmetirom MASLD MASH FGF21 GLP-1
Acesso em linha:	https://www.mdpi.com/2227-9059/12/10/2328
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!